While platform players are going super-wide in their offering, some legal AI startups are going the other way and drilling ...

With uncertainties clouding the outcome, Gokaldas Exports MD Sivaramakrishnan Ganapathi sees status quo as the base case, ...

CEO of the National Infusion Center Association argues against a drug price control policy known as “most favored nation.” ...

SmartEsq’s new gen AI offering aims to automate the side letter compiling process and organize provisions to help users ...

Heyman and Rollins have been hinting at a potential backup plan. The last time they mentioned a surprise, Bronson Reed joined ...

It’s been a while since the WWE Universe last saw Roman Reigns on TV. The Undisputed Tribal Chief has been missing from the ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Growth stocks led a furious market rebound from tariff uncertainty with the higher-beta technology and communication services ...

India wants the U.S. to remove all tariffs—both MFN and country-specific—on high and medium-labour-intensive goods. These ...

The MFN Executive Order is a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its ...

FDA’s public guidance continues to warn that, “under most circumstances,” importing drugs for personal use is unlawful, ...